{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T20:09:11Z","timestamp":1767211751213,"version":"3.37.3"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T00:00:00Z","timestamp":1728777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T00:00:00Z","timestamp":1728777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40257-024-00897-6","type":"journal-article","created":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T20:20:00Z","timestamp":1728850800000},"page":"147-150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Oral Roflumilast in Patients with Psoriasis: A Real-World Cohort Study"],"prefix":"10.1007","volume":"26","author":[{"given":"Mette","family":"Gyldenl\u00f8ve","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoffer Valdemar","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sascha Dinsen Wreschner","family":"Stave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon Francis","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Egeberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2950-3280","authenticated-orcid":false,"given":"Nikolai","family":"Loft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,13]]},"reference":[{"issue":"1","key":"897_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/ced\/llad275","volume":"49","author":"MS Liljendahl","year":"2024","unstructured":"Liljendahl MS, Loft N, Nguyen T-L, Skov L, Egeberg A. Use of systemic and biological therapy in patients with moderate-to-severe psoriasis. Clin Exp Dermatol. 2024;49(1):35\u201341.","journal-title":"Clin Exp Dermatol"},{"key":"897_CR2","doi-asserted-by":"publisher","first-page":"100639","DOI":"10.1016\/j.lanepe.2023.100639","volume":"30","author":"M Gyldenl\u00f8ve","year":"2023","unstructured":"Gyldenl\u00f8ve M, Meteran H, S\u00f8rensen JA, Fage S, Yao Y, Lindhardsen J, et al. Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis\u2014a randomized controlled trial (PSORRO). Lancet Reg Health Eur. 2023;30:100639.","journal-title":"Lancet Reg Health Eur"},{"key":"897_CR3","doi-asserted-by":"publisher","first-page":"12616","DOI":"10.2340\/actadv.v103.12616","volume":"103","author":"N Loft","year":"2023","unstructured":"Loft N, Egeberg A, Isufi D, Rasmussen MK, Bryld LE, Ajgeiy KK, et al. Response to interleukin-17A inhibitors according to prior biologic exposures: a Danish nationwide study. Acta Derm Venereol. 2023;103:12616.","journal-title":"Acta Derm Venereol"},{"key":"897_CR4","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.jaad.2024.01.018","volume":"90","author":"DG Saadi","year":"2024","unstructured":"Saadi DG, El-Komy MH, Khedr H, Shawky N, Hegazy AA, Azzazi Y, et al. A randomized, controlled pilot study of oral roflumilast compared with intramuscular methotrexate for plaque and scalp psoriasis. J Am Acad Dermatol. 2024;90:1063\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"897_CR5","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/bjd.18333","volume":"182","author":"S Mahil","year":"2020","unstructured":"Mahil S, Wilson N, Dand N, Reynolds N, Griffiths C, Emsley R, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol. 2020;182(5):1158\u201366.","journal-title":"Br J Dermatol"},{"issue":"2","key":"897_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/24755303241234292","volume":"9","author":"CW Schwarz","year":"2024","unstructured":"Schwarz CW, Skov L, Egeberg A, Passey A, Lee J, Gorecki P, et al. Characteristics of patients with psoriasis treated with various biologics\u2014a Danish cohort study. J Psoriasis Psoriatic Arthritis. 2024;9(2):51\u201360.","journal-title":"J Psoriasis Psoriatic Arthritis."},{"issue":"8","key":"897_CR7","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/jdv.18126","volume":"36","author":"N Loft","year":"2022","unstructured":"Loft N, Egeberg A, Rasmussen M, Bryld L, Nissen C, Dam T, et al. Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study. J Eur Acad Dermatol Venereol. 2022;36(8):1284\u201391.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00897-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-024-00897-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00897-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T07:48:04Z","timestamp":1737100084000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-024-00897-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,13]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["897"],"URL":"https:\/\/doi.org\/10.1007\/s40257-024-00897-6","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"type":"print","value":"1175-0561"},{"type":"electronic","value":"1179-1888"}],"subject":[],"published":{"date-parts":[[2024,10,13]]},"assertion":[{"value":"23 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Mette Gyldenl\u00f8ve: Outside the submitted work: Speaker honoraria from Galderma Nordic AB. Christoffer Nissen: Outside the submitted work: Served on advisory boards for UCB, LEO Pharma, and AbbVie. Sascha Stave None. Simon Francis Thomsen: Outside the submitted work: Speaker or served on advisory boards for AbbVie, Almirall, Eli Lilly, Galderma, Incyte, Janssen Pharmaceuticals, LEO Pharma, Novartis, Pfizer, Sanofi, UCB Pharma, and Union Therapeutics, and has received research support from AbbVie, Janssen Pharmaceuticals LEO Pharma, Novartis, Sanofi, and UCB Pharma. Alexander Egeberg: Outside the submitted work: Research funding from the Danish Psoriasis Foundation, the Kgl. Hofbuntmager Aage Bang Foundation, the Simon Spies Foundation, Pfizer, Eli Lilly, Novartis, AbbVie, and Janssen Pharmaceuticals. Consultant and\/or speaker honoraria from AbbVie, Almirall, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Galderma, Gal\u00e1pagos NV, Horizon Therapeutics, Janssen Pharmaceuticals, LEO Pharma, Mylan, Novartis, Pfizer, Samsung Bioepis Co., Ltd., UCB, and Union Therapeutics. Currently employed by LEO Pharma. Nikolai Loft: Outside the submitted work: Paid speaker for Eli Lilly, Janssen Cilag, and Sandoz.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interests"}},{"value":"The data that support the findings of this article are available from the corresponding author, upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Conceptualization: Mette Gyldenl\u00f8ve and Alexander Egeberg; Methodology: Mette Gyldenl\u00f8ve and Nikolai Loft; Formal analysis and investigation: Nikolai Loft; Writing\u2014original draft preparation: Mette Gyldenl\u00f8ve and Nikolai Loft; Writing\u2014review and editing: all authors; Funding acquisition: N\/A; Resources: Christoffer Nissen, Simon Francis Thomsen, and Sascha Stave; Supervision: Nikolai Loft and Mette Gyldenl\u00f8ve.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Not required for this register-based study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}